Therapeutic antibodies have become the predominant class of new drugs gaining FDA and have positively impacted the most patients for treating various human diseases, including cancer, autoimmune, and infectious diseases. Over the past 30 years, major technological advances have facilitated the discovery and development of monoclonal antibody therapies, and new strategies are continually emerging to enhance their clinical potential. Though substantial progress has been made, new opportunities and challenges continue to evolve in this rapidly moving field. Multiple advances in antibody technology to expand antibody attributes have already translated into improved clinical activity in multiple therapeutic areas. Yet they also unveil major challenges with respect to target validation, MOA, protein design, development time, and managing increasing costs of antibody manufacturing. The aim of this conference will be to provide a diverse program comprised of academic and industry scientists that addresses the challenges and opportunities relevant to antibody drug discovery and development. Specifically, this conference will focus on 1) target identification and novel discovery platforms, 2) advances in protein engineering to improve functional properties and new antibody modalities and delivery methods and 3) an overview of emerging clinical therapeutics in oncology, infectious disease and autoimmunity/inflammation. We envision this program will offer investigators an overview of antibody therapy development from bench to bedside and also highlight cutting edge technological and clinical advancements of interest to a broad spectrum of scientists.